Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: a comeback?

D Wendling, E Toussirot, F Michel

    Joint Bone Spine
    |August 30, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Thalidomide, once a sedative, caused severe birth defects and was withdrawn. It is now being re-evaluated for potential therapeutic uses in various conditions, with safer analogs developed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A treadmill exercise reduced cardiac fibrosis, inflammation and vulnerability to ischemia-reperfusion in rat pristane-induced arthritis.

    Life sciences·2024
    Same author

    Effectiveness, safety, and cost-utility of a knee brace in medial knee osteoarthritis: the ERGONOMIE randomized controlled trial.

    Osteoarthritis and cartilage·2021
    Same author

    Baricitinib-induced paradoxical psoriasis.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2020
    Same author

    Local ice cryotherapy decreases synovial interleukin 6, interleukin 1β, vascular endothelial growth factor, prostaglandin-E2, and nuclear factor kappa B p65 in human knee arthritis: a controlled study.

    Arthritis research & therapy·2019
    Same author

    Glucocorticoids improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.

    Clinical and experimental immunology·2017
    Same author

    New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2016
    Same journal

    Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

    Joint bone spine·2026
    Same journal

    Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

    Joint bone spine·2026
    Same journal

    What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

    Joint bone spine·2026
    Same journal

    Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

    Joint bone spine·2026
    Same journal

    Multimodal imaging evaluation of the entheses in spondyloarthritis.

    Joint bone spine·2026
    Same journal

    Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

    Joint bone spine·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Teratology
    • Immunology

    Background:

    • Thalidomide, a synthetic glutamic acid derivative, was initially marketed as a sedative in 1954.
    • It gained notoriety due to its teratogenic effects, causing severe birth defects like phocomelia.
    • Market withdrawal followed to prevent further cases of these devastating developmental abnormalities.

    Discussion:

    • Recent research indicates thalidomide possesses therapeutic properties for various medical conditions.
    • Clinical trials are currently investigating its efficacy in treating rheumatic diseases.
    • The development of safer thalidomide analogs aims to mitigate risks associated with the original compound.

    Key Insights:

    • Thalidomide's teratogenicity led to its market removal.

    Related Experiment Videos

  • Emerging evidence supports thalidomide's potential therapeutic applications.
  • Safer analogs are being developed to harness its benefits while minimizing harm.

    • Outlook:

    • Ongoing trials may establish new therapeutic roles for thalidomide and its analogs.
    • Further research into the mechanisms of action could unlock broader clinical utility.
    • The re-evaluation of thalidomide highlights the dynamic nature of drug discovery and repurposing.